Kuschnir, E.

patient infarction thrombolytic therapy thrombolytic therapy heparin iv heparin study trial mortality thrombolysi jam coll cardiol swets subs service angioplasty plasminogen reperfusion cardiol activator circulation artery heart result exercise streptokinase agent thrombolytic agents alteplase tissue plasminogen activator treatment survival stroke minute group j cardiol regimen gusto br heart j 60 minutes tissue-type plasminogen activator cardiogenic shock benefit effect function catheterization heart j disease ischemia onset percutaneous transluminal gissi service patency coll cardiol anistreplase recanalization randomized lancet downloaded surgery shock february administration circ.ahajournals.org reduction 30- day mortality topol ej noninvasive risk stratification incidence tissue aspirin contraindication infarct noninvasive testing stenosi sc heparin reperfusion reperfusion artery disease infarct size werf f